Arcadia Biosciences Files 2023 Annual Report on Form 10-K

TL;DR

<b>Arcadia Biosciences has filed its 2023 10-K report detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

Arcadia Biosciences, Inc. (RKDA) filed a Annual Report (10-K) with the SEC on March 28, 2024. Arcadia Biosciences, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is 202 Cousteau Place, Suite 105, Davis, CA 95618. Arcadia Biosciences is incorporated in Delaware. The filing includes information related to various financial instruments and business segments, such as common stock, warrants, and discontinued operations.

Why It Matters

For investors and stakeholders tracking Arcadia Biosciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Arcadia Biosciences' financial health, operational activities, and strategic positioning for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. The detailed information within the report, including financial statements, risk factors, and executive compensation, allows stakeholders to make informed investment decisions and understand the company's compliance with SEC regulations.

Risk Assessment

Risk Level: medium — Arcadia Biosciences, Inc. shows moderate risk based on this filing. The company's financial disclosures in the 10-K are extensive, indicating a need for careful review of its financial condition and operational risks, which are typical for a company in the agriculture production sector.

Analyst Insight

Investors should carefully review the financial statements and risk factors in the 2023 10-K to understand Arcadia Biosciences' current financial health and strategic direction.

Key Numbers

• 20231231 — Fiscal Year End (Conformed period of report)
• 20240328 — Filing Date (Filed as of date)
• 105 — Public Document Count (Number of documents in the filing)
• 0000950170-24-038176 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Filer name
• 20231231 (date) — Fiscal year end
• 20240328 (date) — Filing date
• 0000950170-24-038176 (filing_id) — Accession number
• 202 COUSTEAU PLACE SUITE 105 DAVIS CA 95618 (address) — Business address
• DE (state) — State of incorporation
• 001-37383 (filing_id) — SEC file number
• RKDA (ticker) — Ticker symbol

FAQ

Industry Context

Arcadia Biosciences operates in the AGRICULTURE PRODUCTION - CROPS sector. This 10-K filing provides insights into its specific business activities within this industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, indicating compliance with regulatory requirements for public companies.

What Investors Should Do

1. Review the detailed financial statements for the fiscal year ended December 31, 2023.
2. Analyze the risk factors section to understand potential challenges and uncertainties facing the company.
3. Examine any disclosures related to business segments, discontinued operations, or significant financial instruments.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2024-03-28: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the 2023 10-K filing, providing the latest annual financial and operational data for Arcadia Biosciences.

Filing Documents

• rkda-20231231.htm (10-K) — 3187KB
• rkda-ex4_7.htm (EX-4.7) — 45KB
• rkda-ex23_1.htm (EX-23.1) — 5KB
• rkda-ex31_1.htm (EX-31.1) — 15KB
• rkda-ex31_2.htm (EX-31.2) — 15KB
• rkda-ex32_1.htm (EX-32.1) — 7KB
• rkda-ex32_2.htm (EX-32.2) — 7KB
• rkda-ex97_1.htm (EX-97.1) — 95KB
• 0000950170-24-038176.txt (&nbsp;) — 15192KB
• rkda-20231231.xsd (EX-101.SCH) — 2531KB
• rkda-20231231_htm.xml (XML) — 2876KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 8 Item 1B. Unresolved Staff Comments 17 Item 1C. Cybersecurity 18 Item 2.

Properties

Properties 18 Item 3.

Legal Proceedings

Legal Proceedings 18 Item 4. Mine Safety Disclosures 18 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19 Item 6. [Reserved] 19 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 32 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 67 Item 9A.

Controls and Procedures

Controls and Procedures 67 Item 9B. Other Information 67 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 67 PART III Item 10. Directors, Executive Officers and Corporate Governance 68 Item 11.

Executive Compensation

Executive Compensation 68 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 68 Item 13. Certain Relationships and Related Transactions, and Director Independence 68 Item 14. Principal Accounting Fees and Services 68 PART IV Item 15. Exhibits, Financial Statement Schedules 69 Item 16. Form 10-K Summary 69 i Table of Contents P ART I

Business

Item 1. Business. Overview We are a producer and marketer of innovative, plant-based food and beverage products. Our history as a leader in science-based approaches to developing high value crop improvements, primarily in wheat, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, has laid the foundation for our path forward. We have used non-genetically modified ("non-GMO") advanced breeding techniques to develop these proprietary innovations which we are now commercializing through the sales of seed and grain, food ingredients and products, trait licensing and royalty agreements. The acquisition of the assets of Live Zola, LLC ("Zola") added coconut water to our portfolio of products. Our commercial strategy is to satisfy consumer nutrition demands with the superior functional benefits our crops deliver directly from the farm, enabling us to share premium economics throughout the ag-food supply chain and to build a world-class estate of high value traits and varieties. The acquisition of the Zola brand allows us to broaden our reach within the beverage sector. Our Growth Strategy We believe there are significant opportunities to grow our business by executing the following elements of our strategy: Accelerate the monetization of our GoodWheat wheat trait portfolio. Our proprietary intellectual property ("IP") with multiple non-GMO wheat traits have clear functional benefits, and we will continue to build partnerships across the wheat value chain. We have launched GoodWheat into multiple categories where our wheat provides a compelling point-of-difference and we will continue to evaluate ways to extract value throughout the supply chain. Evaluate scale M&A opportunities. We intend to evaluate potential mergers, acquisitions, and other strategic opportunities that will allow us to scale the GoodWheat value proposition more quickly. We believe there is a significant opportunit

View Full Filing

View this 10-K filing on SEC EDGAR